Abstract
Most stroke is multifactorial with multiple polygenic risk factors each conferring small increases in risk interacting with environmental risk factors, but it can also arise from mutations in a single gene. This review covers single-gene disorders which lead to stroke as a major phenotype, with a focus on those which cause cerebral small vessel disease (SVD), an area where there has been significant recent progress with findings that may inform us about the pathogenesis of SVD more broadly. We also discuss the impact that next generation sequencing technology (NGST) is likely to have on clinical practice in this area. The most common form of monogenic SVD is cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, due to the mutations in the NOTCH3 gene. Several other inherited forms of SVD include cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy, retinal vasculopathy with cerebral leukodystrophy, collagen type IV α1 and α2 gene-related arteriopathy and FOXC1 deletion related arteriopathy. These monogenic forms of SVD, with overlapping clinical phenotypes, are beginning to provide insights into how the small arteries in the brain can be damaged and some of the mechanisms identified may also be relevant to more common sporadic SVD. Despite the discovery of these disorders, it is often challenging to clinically and radiologically distinguish between syndromes, while screening multiple genes for causative mutations that can be costly and time-consuming. The rapidly falling cost of NGST may allow quicker diagnosis of these rare causes of SVD, and can also identify previously unknown disease-causing variants.
Similar content being viewed by others
References
Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9:689–701
Joutel A, Corpechot C, Ducros A et al (1996) Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383:707–710
Razvi SSM, Davidson R, Bone I, Muir KW (2005) The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry 76:739–741
Narayan SK, Gorman G, Kalaria RN et al (2012) The minimum prevalence of CADASIL in northeast England. Neurology 78:1025–1027
Rutten-Jacobs LC, Kilarski LL, Bevan S et al (2015) Abstract 26: Prevalence of CADASIL and Fabry Disease in a Large Cohort of MRI defined Younger onset Lacunar Stroke. Stroke 46:A26
Adib-Samii P, Brice G, Martin RJ, Markus HS (2010) Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke 41:630–634
Dichgans M, Mayer M, Uttner I et al (1998) The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 44:731–739
Desmond DW, Moroney JT, Lynch T et al (1999) The natural history of CADASIL: a pooled analysis of previously published cases. Stroke 30:1230–1233
Roine S, Pöyhönen M, Timonen S et al (2005) Neurologic symptoms are common during gestation and puerperium in CADASIL. Neurology 64:1441–1443
Hinze S, Goonasekera M, Nannucci S et al (2015) Longitudinally extensive spinal cord infarction in CADASIL. Pract Neurol 15:60–62
Tournier-Lasserve E, Joutel A, Melki J et al (1993) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 3:256–259
O’Sullivan M, Jarosz JM, Martin RJ et al (2001) MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology 56:628–634
Lesnik Oberstein SA, van den Boom R, van Buchem MA et al (2001) Cerebral microbleeds in CADASIL. Neurology 57:1066–1070
Morroni M, Marzioni D, Ragno M et al (2013) Role of electron microscopy in the diagnosis of cadasil syndrome: a study of 32 patients. PLoS One 8:e65482
Singhal S, Bevan S, Barrick T et al (2004) The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 127:2031–2038
Opherk C, Peters N, Holtmannspötter M et al (2006) Heritability of MRI lesion volume in CADASIL: evidence for genetic modifiers. Stroke 37:2684–2689
Fukutake T (2011) Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL): from discovery to gene identification. J Stroke Cerebrovasc Dis 20:85–93
Mendioroz M, Fernández-Cadenas I, Del Río-Espinola A et al (2010) A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population. Neurology 75:2033–2035
Fukutake T, Hirayama K (1995) Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol 35:69–79
Yanagawa S, Ito N, Arima K, Ikeda S-IS (2002) Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Neurology 58:817–820
Arima K, Yanagawa S, Ito N, Ikeda S (2003) Cerebral arterial pathology of CADASIL and CARASIL (Maeda syndrome). Neuropathology 23:327–334
Richards A, van den Maagdenberg AMJM, Jen JC et al (2007) C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 39:1068–1070
Ophoff RA, DeYoung J, Service SK et al (2001) Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1–p21.3. Am J Hum Genet 69:447–453
DiFrancesco JC, Novara F, Zuffardi O et al (2014) TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. Neurol Sci. doi:10.1007/s10072-014-1944-9
Kavanagh D, Spitzer D, Kothari PH et al (2008) New roles for the major human 3′-5′ exonuclease TREX1 in human disease. Cell Cycle 7:1718–1725
Pelzer N, de Vries B, Boon EMJ et al (2013) Heterozygous TREX1 mutations in early-onset cerebrovascular disease. J Neurol 260:2188–2190
Vahedi K, Alamowitch S (2011) Clinical spectrum of type IV collagen (COL4A1) mutations: a novel genetic multisystem disease. Curr Opin Neurol 24:63–68
Lanfranconi S, Markus HS (2010) COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. Stroke 41:e513–e518
Gould DB, Phalan FC, van Mil SE et al (2006) Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 354:1489–1496
Vahedi K, Boukobza M, Massin P et al (2007) Clinical and brain MRI follow-up study of a family with COL4A1 mutation. Neurology 69:1564–1568
Alamowitch S, Plaisier E, Favrole P et al (2009) Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. Neurology 73:1873–1882
Verbeek E, Meuwissen MEC, Verheijen FW et al (2012) COL4A2 mutation associated with familial porencephaly and small-vessel disease. Eur J Hum Genet 20:844–851
Renard D, Miné M, Pipiras E et al (2014) Cerebral small-vessel disease associated with COL4A1 and COL4A2 gene duplications. Neurology 83:1029–1031
Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337:319–335
Clarke JTR (2007) Narrative review: Fabry disease. Ann Intern Med 146:425–433
Orteu CH, Jansen T, Lidove O et al (2007) Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157:331–337
Viana-Baptista M (2012) Stroke and Fabry disease. J Neurol 259:1019–1028
Crutchfield KE, Patronas NJ, Dambrosia JM et al (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746–1749
Rolfs A, Böttcher T, Zschiesche M et al (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794–1796
Baptista MV, Ferreira S, Pinho-E-Melo T et al (2010) Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study––screening genetic conditions in Portuguese young stroke patients. Stroke 41:431–436
Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112–128
Linthorst GE, Vedder AC, Aerts JMFG, Hollak CEM (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353:201–203
Schiffmann R, Kopp JB, Austin HA et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749
Siegenthaler JA, Choe Y, Patterson KP et al (2013) Foxc1 is required by pericytes during fetal brain angiogenesis. Biol Open 2:647–659
Tümer Z, Bach-Holm D (2009) Axenfeld-Rieger syndrome and spectrum of PITX2 and FOXC1 mutations. Eur J Hum Genet 17:1527–1539
Delahaye A, Khung-Savatovsky S, Aboura A et al (2012) Pre- and postnatal phenotype of 6p25 deletions involving the FOXC1 gene. Am J Med Genet A 158A:2430–2438
Cellini E, Disciglio V, Novara F et al (2012) Periventricular heterotopia with white matter abnormalities associated with 6p25 deletion. Am J Med Genet A 158A:1793–1797
French CR, Seshadri S, Destefano AL et al (2014) Mutation of FOXC1 and PITX2 induces cerebral small-vessel disease. J Clin Invest 124:4877–4881
Revesz T, Holton JL, Lashley T et al (2009) Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 118:115–130
Di Fede G, Giaccone G, Tagliavini F (2013) Hereditary and sporadic beta-amyloidoses. Front Biosci (Landmark Ed) 18:1202–1226
Biffi A, Greenberg SM (2011) Cerebral amyloid angiopathy: a systematic review. J Clin Neurol 7:1–9
Linn J, Halpin A, Demaerel P et al (2010) Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 74:1346–1350
Greenberg SM, Vernooij MW, Cordonnier C et al (2009) Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 8:165–174
Bacskai BJ, Frosch MP, Freeman SH et al (2007) Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 64:431–434
Baron J-C, Farid K, Dolan E et al (2014) Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab 34:753–758
Rannikmäe K, Davies G, Thomson PA et al (2015) Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease. Neurology. doi:10.1212/WNL.0000000000001309
Schmidt H, Zeginigg M, Wiltgen M et al (2011) Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain 134:3384–3397
Oka C, Tsujimoto R, Kajikawa M et al (2004) HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development 131:1041–1053
Shiga A, Nozaki H, Yokoseki A et al (2011) Cerebral small-vessel disease protein HTRA1 controls the amount of TGF-1 via cleavage of proTGF- 1. Hum Mol Genet 20:1800–1810
Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E et al (2007) TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74:196–206
Gunda B, Mine M, Kovács T et al (2014) COL4A2 mutation causing adult onset recurrent intracerebral hemorrhage and leukoencephalopathy. J Neurol 261:500–503
Farrall AJ, Wardlaw JM (2009) Blood-brain barrier: ageing and microvascular disease––systematic review and meta-analysis. Neurobiol Aging 30:337–352
Kopan R, Ilagan MXG (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216–233
Joutel A, Vahedi K, Corpechot C et al (1997) Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350:1511–1515
Rutten JW, Boon EMJ, Liem MK et al (2013) Hypomorphic NOTCH3 alleles do not cause CADASIL in humans. Hum Mutat 34:1486–1489
Ruchoux MM, Domenga V, Brulin P et al (2003) Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am J Pathol 162:329–342
Joutel A, Andreux F, Gaulis S et al (2000) The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 105:597–605
Duering M, Karpinska A, Rosner S et al (2011) Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. Hum Mol Genet 20:3256–3265
Arboleda-Velasquez JF, Manent J, Lee JH et al (2011) Hypomorphic Notch 3 alleles link Notch signaling to ischemic cerebral small-vessel disease. Proc Natl Acad Sci 108:E128–E135
Monet-Leprêtre M, Haddad I, Baron-Menguy C et al (2013) Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. Brain 136:1830–1845
Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45–51
Kast J, Hanecker P, Beaufort N et al (2014) Sequestration of latent TGF-β binding protein 1 into CADASIL-related Notch3-ECD deposits. Acta Neuropathol Commun 2:96
Ng SB, Buckingham KJ, Lee C et al (2010) Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 42:30–35
Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE (2013) Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 14:681–691
Low WC, Junna M, Börjesson-Hanson A et al (2007) Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL. Brain 130:357–367
Nannucci S, Pescini F, Bertaccini B et al (2015) Clinical, familial, and neuroimaging features of CADASIL-like patients. Acta Neurol Scand 131:30–36
Foo J-N, Liu J-J, Tan E-K (2012) Whole-genome and whole-exome sequencing in neurological diseases. Nat Rev Neurol 8:508–517
Vrijenhoek T, Kraaijeveld K, Elferink M et al (2015) Next-generation sequencing-based genome diagnostics across clinical genetics centers: implementation choices and their effects. Eur J Hum Genet. doi:10.1038/ejhg.2014.279
Genomics England Ltd Genomics England|100,000 genomes project. http://www.genomicsengland.co.uk/. Accessed 3 May 2015
Bamshad MJ, Ng SB, Bigham AW et al (2011) Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 12:745–755
Guerreiro R, Brás J, Hardy J, Singleton A (2014) Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. Hum Mol Genet 44:1–7
Acknowledgments
Rhea Tan is supported by the Agency for Science, Technology and Research Singapore. Hugh Markus is supported by an NIHR Senior Investigator award. His work is supported by the Cambridge Universities Trust NIHR Comprehensive Biomedical Research Centre.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical standard
The manuscript does not contain clinical studies or patient data.
Author information
Authors and Affiliations
Corresponding author
Box 1: Features that heighten clinical suspicion of a monogenic cause of SVD. Note many of these are indicators but not diagnostic. For example, CADASIL can occur in patients with risk factors which may indeed exacerbate the phenotype
Box 1: Features that heighten clinical suspicion of a monogenic cause of SVD. Note many of these are indicators but not diagnostic. For example, CADASIL can occur in patients with risk factors which may indeed exacerbate the phenotype
Clinical presentation
-
Onset of stroke at an early age.
-
Syndromic disease: history of other clinical features which fit with recognised monogenic stroke syndrome:
-
Other neurological history such as complicated migraines, seizures, early-onset cognitive impairment, psychiatric disturbances.
-
Non-neurological features such as skeletal, facial, ocular abnormalities.
-
Risk factors and other causes of white matter disease
-
The absence of identifiable risk factors such as diabetes, hypertension or smoking.
-
The absence of any other cause of stroke.
Family history
-
A family history of early-onset stroke or dementia, especially if this is occurring in a Mendelian pattern of inheritance.
Presence of atypical features of imaging, such as
-
Evidence of SVD beyond what is expected for age and risk factors.
-
Atypical distribution of white matter hyperintensities on T2/FLAIR MRI in anterior temporal poles and external capsule as seen in CADASIL.
-
Extensive microbleeds particularly in COL4A1/2 mutations.
-
Pseudotumours as seen in RVCL.
-
Vascular malformations such as aneurysms (COL4A1), dolichoectasia (Fabry Disease).
Rights and permissions
About this article
Cite this article
Tan, R.Y.Y., Markus, H.S. Monogenic causes of stroke: now and the future. J Neurol 262, 2601–2616 (2015). https://doi.org/10.1007/s00415-015-7794-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-015-7794-4